Tickernomics

10y

Historical Returns*:

SPY

27.80%

-21.88%

BCYC

SPY

32.66%

-75.46%

BCYC

SPY

108.59%

BCYC

60.97%

SPY

302.52%

BCYC

0.00%

*Assumes dividends reinvested

Market Stats:

Market Capitalization($MM)

Enterprise Value($MM)

Daily Volume(MM)

763.24

-116.71

0.17

Valuation Metrics:

Price/Earnings Ratio

Price/Sales Ratio

Price/Book Value

FCF Yield(%)

Dividend Yield(%)

EV/EBITDA

-4.59

20.69

0.92

-16.87

0.00

0.59

Profitability Stats:

Operating Margin %(ttm)

Gross Profit %(ttm)

EBITDA Margin %(ttm)

-2385.87

100.00

-579.27

Shareholder Value Creation:

Cost of Capital %(est)

ROIC %(ttm)

ROCE %(ttm)

Beta

7.1168

-44.22

-46.67

0.76

Other Earnings and Cash Flow Stats:

BICYCLE THERAPEUTICS PLC ( BCYC ) Net Income TTM ($MM) is -166.28

BICYCLE THERAPEUTICS PLC ( BCYC ) Operating Income TTM ($MM) is -196.44

BICYCLE THERAPEUTICS PLC ( BCYC ) Owners' Earnings Annual ($MM) is 0.00

BICYCLE THERAPEUTICS PLC ( BCYC ) Current Price to Owners' Earnings ratio is 0.00

BICYCLE THERAPEUTICS PLC ( BCYC ) EBITDA TTM ($MM) is -189.29

BICYCLE THERAPEUTICS PLC ( BCYC ) EBITDA Margin is -579.27%

Capital Allocation:

BICYCLE THERAPEUTICS PLC ( BCYC ) has paid 0.00 dividends per share and bought back -12.415567 million shares in the past 12 months

BICYCLE THERAPEUTICS PLC ( BCYC ) has reduced its debt by 39.444 million USD in the last 12 months

Capital Structure:

BICYCLE THERAPEUTICS PLC ( BCYC ) Interest-bearing Debt ($MM) as of last quarter is 10

BICYCLE THERAPEUTICS PLC ( BCYC ) Annual Working Capital Investments ($MM) are -5

BICYCLE THERAPEUTICS PLC ( BCYC ) Book Value ($MM) as of last quarter is 831

BICYCLE THERAPEUTICS PLC ( BCYC ) Debt/Capital as of last quarter is 1%

Other Balance Sheet Stats:

BICYCLE THERAPEUTICS PLC ( BCYC ) has 890 million in cash on hand as of last quarter

BICYCLE THERAPEUTICS PLC ( BCYC ) has 56 million of liabilities due within 12 months, and long term debt 30 as of last quarter

BICYCLE THERAPEUTICS PLC ( BCYC ) has 51 common shares outstanding as of last quarter

BICYCLE THERAPEUTICS PLC ( BCYC ) has 0 million USD of preferred stock value

Academic Scores:

BICYCLE THERAPEUTICS PLC ( BCYC ) Altman Z-Score is 2.33 as of last quarter

BICYCLE THERAPEUTICS PLC ( BCYC ) Piotroski Score is 3.00 as of last quarter

Corporate Governance:

BICYCLE THERAPEUTICS PLC ( BCYC ) largest shareholder is owning shares at 0.00 ($MM) value

BAKER BROS. ADVISORS LP; 667, L.P.(an insider) Bought 457631 shares of BICYCLE THERAPEUTICS PLC ( BCYC ) for the amount of $7020883.28 on 2024-12-16

1.31% of BICYCLE THERAPEUTICS PLC ( BCYC ) is held by insiders, and 91.66% is held by institutions

BICYCLE THERAPEUTICS PLC ( BCYC ) went public on 2019-05-23

About BICYCLE THERAPEUTICS PLC ( BCYC ) :

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.